Search Results - "Goyvaerts, C"

Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery by Goyvaerts, C, De Vlaeminck, Y, Escors, D, Lienenklaus, S, Keyaerts, M, Raes, G, Breckpot, K

“…Targeting transgene expression specifically to antigen-presenting cells (APCs) has been put forward as a promising strategy to direct the immune system towards…”
Get full text

Lentiviral vectors: a versatile tool to fight cancer by Emeagi, P U, Goyvaerts, C, Maenhout, S, Pen, J, Thielemans, K, Breckpot, K

“…Over the years, there has been an exponential increase in the number of gene therapy approaches that are under investigation for the treatment of cancer. This…”
Get more information

Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer by Lecocq, Q., Debie, P., Puttemans, J., Awad, R. M., De Beck, L., Ertveldt, T., De Vlaeminck, Y., Goyvaerts, C., Raes, G., Keyaerts, M., Breckpot, K., Devoogdt, N.

“…Recent advancements in the field of immune-oncology have led to a significant increase in life expectancy of patients with diverse forms of cancer, such as…”
Get full text

Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells by Goyvaerts, C, De Groeve, K, Dingemans, J, Van Lint, S, Robays, L, Heirman, C, Reiser, J, Zhang, X-Y, Thielemans, K, De Baetselier, P, Raes, G, Breckpot, K

“…Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ ,…”
Get full text

1096P Identifying predictive biomarkers for long term response on immunotherapy in non-small cell lung cancer (NSCLC) by Decoster, L., Nazari, S., De Ridder, K., Giron, P., Vekens, K., Goyvaerts, C.

Get full text

20P Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma by Awada, G., Schwarze, J.K., Reijmen, E., Goyvaerts, C., Fasolino, G., Aspeslagh, S., Neyns, B.

Get full text

Fractionated Radiation Severely Reduces the Number of CD8+ T Cells and Mature Antigen Presenting Cells Within Lung Tumors by Reijmen, Eva, De Mey, Sven, De Mey, Wout, Gevaert, Thierry, De Ridder, Kirsten, Locy, Hanne, Martens, Sandrina, De Blay, Emmy, Bouwens, Luc, Debie, Pieterjan, Breckpot, Karine, De Grève, Jacques, De Ridder, Mark, Goyvaerts, Cleo

“…The combination of standard-of-care radiation therapy (RT) with immunotherapy is moving to the mainstream of non-small cell lung cancer treatment. Multiple…”
Get full text

Development of LAG-3 nanobodies as potent cancer imaging tracers by Lecocq, Q., Awad, R.M., Zeven, K., De Vlaeminck, Y., de Mey, W., Debie, P., Puttemans, J., Goyvaerts, C., Raes, G., Keyaerts, M., Devoogdt, N., Breckpot, K.

Get full text

168P Characterization of the lung tumor microenvironment upon anti-PD-L1 therapy reveals an ambiguous role for TNF-α by De Ridder, K., Locy, H., Piccioni, E., Ibarra Zuazo, M., Awad, R.M., Verhulst, S., van Bulck, M., De Vlaeminck, Y., Lecocq, Q., Reijmen, E., De Mey, W., De Beck, L., Ertveldt, T., Pintelon, I., Timmermans, J-P., Escors, D., Keyaerts, M., Breckpot, K., Goyvaerts, C.

Get full text